Background
==========

Adolescent primary amenorrhea is a frequent reason for consultation in pediatric and gynecological endocrine clinics. Primary amenorrhea may result from congenital abnormalities in gonadal or genital tract development or from a defect in the hypothalamic-pituitary-ovarian axis. Failure to menstruate by the age of 15 years requires investigation to determine the cause and establish a treatment plan. The standard investigation includes detailed clinical evaluation \[[@B1]\], endocrine assessment (gonadotropins, testosterone, AMH and inhibin B assays) and pelvic imaging. In addition, genetic exploration is crucial to classify the primary amenorrhea. Karyotyping, which discriminates normal from abnormal chromosomes (i.e., 45,X0 or 46,XY), is the first step. In the 46,XY disorders of sex differentiation (DSD) \[[@B2]\], primary amenorrhea may be caused by a genetic defect in fetal testis determination, failure of the fetal testis to produce testosterone, or androgen resistance \[[@B3]\]. The assessment of endocrine parameters thus often orients the exploration toward the most probable genetic cause \[[@B4]\]. For example, when plasma testosterone (pl-T) is low, an abnormality in the genes involved in fetal testis determination, such as *SRY*, *SF1*, *WT1*, *SOX9, DMRT, DHH, DAX1*and *WNT4*, should be considered \[[@B5]\].

Here we describe a two-year experience of genetic exploration in adolescents with primary amenorrhea due to 46,XY DSD and low pl-T concentration. We specifically focused on *SRY, SF1*and *WT1*because these genes have previously been reported to be implicated in adolescents presenting with primary amenorrhea due to 46,XY DSD in association with low pl-T, but no other signs. Our aim was thus to assess the frequency of mutations in these genes in a cohort of 15 adolescents with this profile. We identified eight unreported mutations in these genes responsible for testis differentiation and development: two new mutations in *SRY*and five new mutations in *SF1*. Moreover, in a patient with a specific biological profile of elevated LH and normal FSH concentrations, we identified a new *LH receptor*mutation. Thus far, we have been unable to determine a genetic cause for the primary amenorrhea in the seven remaining subjects.

Methods
=======

Patient cohorts
---------------

Over a two-year period (2007-2009), we studied 31 adolescent patients with primary amenorrhea due to 46,XY DSD who had been referred by collaborating centers to the gynecological unit of our pediatric endocrine clinic or to our genetics laboratory. All patients had a 46,XY karyotype. We were able to classify these adolescents with primary amenorrhea into two main groups. The first group was composed of 16 patients with high pl-T concentrations, whereas the second group comprised 15 patients with low pl-T (\< 0.4 ng/ml) and elevated gonadotropins (Table [1](#T1){ref-type="table"}). We focused our study on the second group. The phenotype of most of these patients was female and 5/15 of them presented with isolated clitoromegaly (Table [1](#T1){ref-type="table"}).

###### 

Clinical, endocrine and genetic features of the 15 adolescents with primary amenorrhea and low testosterone

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
               External genitalia             Tanner stages   Uterus    Gonads pathology                                           T (ng/ml)    FSH (UI/l)   LH (UI/l)   Mutation              Inheritance    Protein consequences
  ------------ ------------------------------ --------------- --------- ---------------------------------------------------------- ------------ ------------ ----------- --------------------- -------------- --------------------------
  Patient 1    Normal female                  B3P3            Present   Streak gonads                                              0.66         33           9.4         *SRY*: c.292T\>C      Hemizygous     p.Trp98Arg

  Patient 2    Normal female                  ND              Present   ND                                                         \< 0.1       13           2           *SRY*: c.319insA      Hemizygous     p.Trp107Met*fsX21*

  Patient 3    Normal female                  ND              ND        ND                                                         \< 0.1       ND           ND          *SF1*: c.1A\>G        Heterozygous   p.Met1Val (probably p.0)

  Patient 4    Clitoromegaly                  ND              ND        Gonads in labia                                            \< 0.1       ND           ND          *SF1*: c.116G\>C      Heterozygous   p.Arg39Pro

  Patient 5    Clitoromegaly                  ND              ND        Testicular tissue/inguinal region                          0.7          ND           ND          *SF1*: c.151delG      Heterozygous   p.Glu51Arg*fsX23*

  Patient 6    Clitoromegaly + Virilization   ND              ND        ND                                                         2,2\         ND           ND          *SF1*: c.369insC      Heterozygous   p.Pro124Pro*fsX24*
                                                                                                                                   (post HCG)                                                                 

  Patient 7    Normal female                  B1A2P5          Present   ND                                                         0.3          40           18          *SF1*: c.1138G\>T     Heterozygous   p.Asp380Tyr

  Patient 8    Normal female                  B1A3P3          ND        Presence of Sertoli cells                                  0.33         8.7          11.2        *LHCGR*: c.1395G\>A   Homozygous     p.Trp465X

  Patient 9    Normal female                  ND              Absent    Streak gonads                                              0.35         102          28          None                  \-             \-

  Patient 10   Normal female                  B1P1            ND        ND                                                         0.38         135          42          None                  \-             \-

  Patient 11   Clitoromegaly + Hirsutism      ND              Present   Gonadoblastoma                                             0.3          ND           ND          None                  \-             \-

  Patient 12   Normal female                  ND              Present   Streak gonads                                              \< 0.1       78           46          None                  \-             \-

  Patient 13   Normal female                  ND              ND        Gonadal dysgenesis                                         \< 0.1       59           45.8        None                  \-             \-

  Patient 14   clitoris and labia agenesis    B2P4            Present   Left dysgerminoma, Right fibrous structure (few tubules)   0.14         71.7         18.6        None                  \-             \-

  Patient 15   Clitoromegaly                  B1P4            Absent    ND                                                         0.3          56.3         29.5        None                  \-             \-
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Normal ranges: basal T, 0.35-0.9 ng/ml; FSH, 1-12 UI/l; LH, 1-5 UI/l. Conversion to SI: T ng/ml × 3,47 for nmol/l.

ND: Not Determined

Mutation analysis
-----------------

With the informed consent of the patients and/or their parents, DNA was extracted from peripheral blood leukocytes. The study was approved by the institutional review boards of all collaborating hospitals. The entire coding region and splice sites of the *SRY*, *NR5A1*(*SF1*) and Wilm\'s tumor (*WT1*) genes were PCR-amplified using previously described primers and conditions \[[@B6]-[@B8]\] and sequenced directly using BigDye terminator v1.1 (Applied Biosystems) and an ABI Prism 3130 genetic analyzer (Applied Biosystems).

Predicted SRY and SF1 mutation effects
--------------------------------------

Amino acid substitutions were studied *in silico*to predict the effects. We performed the *in silico*analysis using two software packages, PolyPhen \[[@B9]\] and SIFT \[[@B10]\]. The PolyPhen algorithm is able to predict the functional effects of amino acid changes by considering evolutionary conservation, physicochemical differences, and the proximity of the substitution to predicted functional domains and/or structural features. The SIFT algorithm predicts the functional importance of amino acid substitutions based on the alignment of orthologous and/or paralogous protein sequences. Scores lower than 0.05 suggest the potential pathogenicity of mutations. The original protein sequences were obtained from the Ensembl and UniProt/Swiss-Prot databases.

Results
=======

Mutation analysis
-----------------

Direct sequencing of *SRY*revealed two new mutations in patients 1 and 2 (Table [1](#T1){ref-type="table"}). Patient 1 showed a variant, c.292T\>C, leading to the amino acid p.Trp98Arg substitution in a highly conserved HMG domain (Figure [1](#F1){ref-type="fig"}). This variant was absent in 100 control chromosomes. In patient 2, we identified a new nucleotide insertion in *SRY*(c.319insA). This insertion led to a premature stop codon 21 amino acids after the mutated codon in the DNA binding domain, which doubtlessly abolished the *SRY*function.

![**Representation of SRY gene (A) and protein (B) showing the localization of mutations identified in adolescents with primary amenorrhea due to 46,XY DSD**.](1477-7827-8-28-1){#F1}

When the *SRY*sequence was normal, we systematically studied the *SF1*and *WT1*sequences. We identified five new heterozygous *SF1*mutations in patients 3, 4, 5, 6 and 7 (Table [1](#T1){ref-type="table"}). Among them, three were nucleotide substitutions: c.1A\>G (p.Met1Val) for patient 3, c.116G\>C (p.Arg39Pro) for patient 4, and c.1138G\>T (p.Asp380Tyr) for patient 7. The two other *SF1*mutations were a deletion, c.151delG, for patient 5 and an insertion, c.369insC, for patient 6 (Figure [2](#F2){ref-type="fig"}). These mutations led to a frame shift with a premature stop codon 23 and 24 amino acids later, respectively. Proteins resulting from these mutations are predicted to have null activity. No mutation of *WT1*was identified in our group.

![**Representation of SF1 gene (A) and protein (B) showing the localization of mutations identified in adolescents with primary amenorrhea due to 46,XY DSD**.](1477-7827-8-28-2){#F2}

As patient 8 had elevated LH and normal FSH concentrations (Table [1](#T1){ref-type="table"}), we performed *LHCGR*analysis. The direct sequencing of this gene revealed a new homozygous LH receptor mutation, c.1395G\>A (p.Trp465X), leading to a stop codon that causes an aberrant transmembrane domain (Figure [3](#F3){ref-type="fig"}). As most of the transmembrane domain was missing, it was certain that the LH receptor was non-functional.

![**Representation of LHCGR gene (A) and protein (B) showing the localization of mutations identified in adolescents with primary amenorrhea due to 46,XY DSD**.](1477-7827-8-28-3){#F3}

Prediction of missense mutation effects
---------------------------------------

We used two software packages to predict the functional effects of the amino acid substitutions. First, we performed testing with PolyPhen \[[@B11]\]. Except for the missense mutation affecting the initiating codon, all missense substitutions were classed as \"probably damaging\".

The same assessment was performed with SIFT \[[@B12]\]. Similar to the PolyPhen method, the SIFT score for these *SRY*and *SF1*substitutions was 0.00, except for p.Met1Val, which cannot be predicted by this software. This score placed the missense mutations in the \"Affects protein function\" class and confirmed the evaluation by the PolyPhen algorithm.

The other mutations were an insertion and a deletion, and the prediction software was unable to assess their deleterious effects. However, these mutations lead rapidly to premature stop codons and truncated proteins, with probably altered function. For the LH receptor, prediction of the nonsense mutation effects was not necessary since the amino acid substitution leads to a stop codon within the transmembrane domain and results in a protein with no intracellular domain.

Discussion
==========

Primary amenorrhea is a frequent reason for consultation in pediatric endocrine and gynecology clinics. Three types of primary amenorrhea can be observed: (1) 46,XX amenorrhea with high FSH concentration, which usually corresponds to a reduction in the number of primary follicles, accelerated follicular atresia, or follicular dysfunction; (2) 45,X0 amenorrhea associated with Turner syndrome; and (3) amenorrhea due to 46,XY DSD. This last can be further classified into two subtypes. The first is defined by primary amenorrhea with normal or high testosterone concentration, suggesting androgen insensitivity syndrome or possibly 5-alpha reductase type 2 deficiency. The second is defined by primary amenorrhea with low testosterone concentration. The etiologies are multiple and testis determination genes such as *SRY*, *SF1*or *WT1*should be explored.

In our 31 adolescents with primary amenorrhea due to 46,XY DSD, 16 showed high testosterone concentrations and, as expected, *AR*gene mutation was a major cause among those who presented with breast development (B5) contrasting with an absence of pubic hair (P1) (data not presented). For the group with low testosterone concentration and considered as 46,XY gonadal dysgenesis \[[@B13]\], we systematically analyzed *SRY*, *SF1*and *WT1*genes, beginning with *SRY*. Gene analysis identified two new *SRY*mutations (2/15). This frequency (13.3%) is similar to that usually reported in the literature, which varies from 10 to 15% \[[@B14]\], and suggests that our cohort was representative of the population of adolescents with primary amenorrhea due to 46,XY DSD and low pl-T.

Patients without *SRY*gene mutations were analyzed for defects in *WT1*or *SF1*. *WT1*is normally associated with Frasier or Denys-Drash syndrome. In our experience with this gene analysis, we have identified a mutation three times in patients with no sign of kidney abnormality or cancer (unpublished). However, no cases of *WT1*abnormality were noted in the present study group.

In contrast, we identified five new *SF1*mutations in this cohort (5/15), which amounts to one third of the cases of primary amenorrhea due to 46,XY DSD with low pl-T level and 5/31 of the cases of primary amenorrhea due to 46,XY DSD. Among these new mutations, three nucleotide substitutions, one insertion and one deletion were identified.

Although *in vitro*studies are needed to demonstrate the implication of these mutations, two of our *SF1*mutations and the *SRY*insertion certainly abolished activity since an insertion or deletion creates a frame shift and premature stop codon. The p.M1V *SF1*mutant probably abolished the transcriptional initiation. An alternative initiation codon is located downstream at codon 78, after the DNA-binding domain, and probably altered the SF1 function. A similar mutation in the initiation codon (p.Met1Ile) was reported in a girl with hypertrophic clitoris, which confirms the impact of this abnormality \[[@B15]\]. These three cases are similar to the cases of haploinsufficiency reported by our group and others \[[@B16]-[@B18]\] in patients with complete sex reversal. For the two other *SF1*missense mutations and the *SRY*substitution reported here, the functional effects predicted by the two types of software were concordant, with the same conclusion of affected protein mutants. These predictions agreed with the phenotype and hormonal data observed in our patients, and we can conclude that these mutations were probably the cause of the phenotype and the biological abnormalities.

We analyzed the LH receptor gene in one of the girls of our cohort because of high LH contrasting with normal FSH concentration \[[@B19]\]. We were thus able to identify a previously unreported *LHCGR*mutation leading to an inactive truncated LH receptor.

For the seven primary amenorrhea adolescents with low pl-T concentrations and no mutation in any of the studied genes, it is probable that one of the other genes implicated in DSD was mutated. The absence of associated signs was a supplementary difficulty for the orientation of genetic exploration, but further gene analysis is warranted to identify the etiology of the DSD observed in these patients. Any one of several genes could be involved, such as *SOX9*, *DMRT*, or *DHH*, as well as duplications of *DAX1*or *WNT4*. However, these genes are not often found to be mutated, especially without specific associated signs.

Conclusions
===========

To conclude, the genetic analysis of low-testosterone primary amenorrhea due to 46,XY DSD is complex since several factors may be involved, including SRY, SF1, WT1 and LH receptor. We confirmed that *SRY*was mutated in about 10 to 15% of the cases. More interestingly, we identified new *SF1*mutations in five of our 15 patients. As this amounts to one third of our cohort, we suggest that the *SF1*sequence should be systematically analyzed in girls with primary amenorrhea due to 46,XY DSD and low testosterone concentration, as well as in newborns with 46,XY DSD.
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